RBBP7

Histone-binding protein RBBP7 · Q16576 · RBBP7 on Sugi Atlas →

4,688 patent compounds predicted against RBBP7, 3,756 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL2591826	0.66	6/20
Riboflavin (SCHEMBL7706)	1.00	4/20
Riboflavin (SCHEMBL7707)	1.00	4/20
SCHEMBL182061	1.00	4/20
SCHEMBL182062	1.00	4/20
Riboflavin (SCHEMBL297531)	1.00	4/20
Riboflavin (SCHEMBL341564)	1.00	4/20
Riboflavin (SCHEMBL2420598)	1.00	4/20
Riboflavin (SCHEMBL1983532)	0.98	4/20
Riboflavin (SCHEMBL246757)	0.96	4/20
Riboflavin (SCHEMBL1064647)	0.96	4/20
Riboflavin (SCHEMBL50096)	0.92	4/20
Riboflavin (SCHEMBL826819)	0.92	4/20
Riboflavin (SCHEMBL2127865)	0.92	4/20
Riboflavin (SCHEMBL2798981)	0.92	4/20
Riboflavin (SCHEMBL2799105)	0.92	4/20
Riboflavin (SCHEMBL2799109)	0.92	4/20
Riboflavin (SCHEMBL2799507)	0.92	4/20
SCHEMBL2595231	0.91	4/20
Riboflavin (SCHEMBL2241200)	0.90	4/20

Clinical trials — most relevant to RBBP7 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt	PHASE4	COMPLETED
Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients	PHASE3	UNKNOWN
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS	PHASE2	COMPLETED
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma	PHASE1/PHASE2	COMPLETED
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL	PHASE1/PHASE2	RECRUITING
Vorinostat in Children	PHASE1/PHASE2	COMPLETED
Treatment With Azacitidine of Recurrent Gliomas With IDH1/2 Mutation	PHASE2	UNKNOWN
LBH589 Treatment for Refractory Clear Cell Renal Carcinoma	PHASE2	COMPLETED
Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma	PHASE1/PHASE2	COMPLETED
Phase II Study of Vandetanib in Individuals With Kidney Cancer	PHASE2	COMPLETED
Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft TIssue Sarcoma After Pre-treatment Failure	PHASE2	COMPLETED
Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer	PHASE2	COMPLETED
IST Neoadjuvant Abraxane in Newly Diagnosed Breast Cancer	PHASE2	UNKNOWN
Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load	PHASE1	COMPLETED
A Phase I Study of Systemic Gene Therapy With SGT-94 in Patients With Solid Tumors	PHASE1	COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome	PHASE1	COMPLETED
Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma	PHASE1	UNKNOWN
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck	PHASE1	COMPLETED
Novel Molecular Targets and Innovative Therapeutic Perspective in Medulloblastoma	EARLY_PHASE1	RECRUITING
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics	nan	UNKNOWN
Study of Proteins in Head and Neck Cancer Cells	nan	COMPLETED
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia	nan	UNKNOWN
Diagnosis of RSTS: Identification of the Acetylation Profiles as Epigenetic Markers for Assessing Causality of CREBBP and EP300 Variants.	nan	UNKNOWN
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients	nan	RECRUITING
Profiles of Expression in HPV+ Versus HPV Head and Neck Cancers	nan	UNKNOWN
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma	nan	UNKNOWN
The Development of Human Papillomavirus Type 16 E7-Specific Human Immunologic Assays in Non-HLA2 Type Human Being	nan	UNKNOWN
Gene Expression Variation and Implant Wound Healing Among Smokers and Diabetics	nan	COMPLETED
EPIgenetics and in Vivo Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase Inhibitors	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a RBBP7 binder may also engage these)

Protein	Name	Similarity
Q71UF4	—	1.000	Q71UF4 →
Q4R304	—	1.000	Q4R304 →
Q60973	—	1.000	Q60973 →
Q3SWX8	—	1.000	Q3SWX8 →
Q9I8G9	—	1.000	Q9I8G9 →
Q24572	—	1.000	Q24572 →
Q5R654	—	1.000	Q5R654 →
Q6P315	—	0.992	Q6P315 →
Q8AVH1	—	0.990	Q8AVH1 →
Q7ZTY4	—	0.988	Q7ZTY4 →
O93377	—	0.957	O93377 →
Q6P3H7	—	0.944	Q6P3H7 →
Q5M7K4	—	0.942	Q5M7K4 →
Q6INH0	—	0.938	Q6INH0 →
Q9W7I5	—	0.933	Q9W7I5 →
Q3MHL3	—	0.929	Q3MHL3 →
Q5RF92	—	0.928	Q5RF92 →
DCAF7	DDB1- and CUL4-associated factor 7	0.927	landscape →
RBBP4	Histone-binding protein RBBP4	0.923	landscape →
Q60972	—	0.923	Q60972 →
Q9BQ87	—	0.923	Q9BQ87 →
P61963	—	0.922	P61963 →
Q8BHJ5	—	0.915	Q8BHJ5 →
Q5RE95	—	0.915	Q5RE95 →
Q86VZ2	—	0.914	Q86VZ2 →
Q6GPC6	—	0.912	Q6GPC6 →
Q9V3J8	—	0.911	Q9V3J8 →
Q9QXE7	—	0.911	Q9QXE7 →
TBL1XR1	F-box-like/WD repeat-containing protein TBL1XR1	0.910	landscape →
Q4R8H1	—	0.910	Q4R8H1 →